Market Pulse
KIS quote snapshot · Sep 21, 2026 11:00 KST · KIS quote snapshots + ECOS · 30 min refresh
KOSPI
6,984.85
+90.62 (+1.31%)
KOSDAQ
835.91
+8.79 (+1.06%)
KOSPI 200
1,108.10
+17.87 (+1.64%)
USD/KRW
1,383.30
207940KOSPI·Jan 23, 2025
Globally leading CDMO in terms of growth and margins
Mirae Asset Securities published a company analysis report on Samsung Biologics (207940) titled "Globally leading CDMO in terms of growth and margins".
Summary
Covers Samsung Biologics (207940).
Covered stock
More on 207940
Order concerns ease as growth drivers expandMirae Asset Securities · Jul 27, 2026Initiating Coverage: Unwavering Growth, Time to Build ConvictionKB Securities · May 27, 2026Fair value of W106trMirae Asset Securities · Nov 24, 2025Spin-off likely to unlock additional valueMirae Asset Securities · Oct 29, 2025Positioning for the next leg of growthMirae Asset Securities · Jul 25, 2025CDMO and biosimilar businesses to be separatedMirae Asset Securities · May 23, 2025Earnings surpass heightened expectationsMirae Asset Securities · Apr 24, 2025